Description
This study identifies oligodendrocytes as drivers of neuroinflammation in PD, contradicting the established paradigm that microglia are the primary neuroinflammatory cells. Understanding this cell-type hierarchy is crucial for targeting the right therapeutic cells.
Gap type: contradiction Source paper: Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson’s disease via the prosaposin-GPR37-IL-6 axis. (2025, Cell Rep, PMID:39913287)
Resolution criteria
Resolution requires: (1) Temporal cell-type-specific ablation experiments in a PD model demonstrating that oligodendrocyte-specific deletion of p38 MAPK or equivalent inflammatory pathway reduces microglial activation by ≥40% and precedes (not follows) dopaminergic neuron loss; (2) Conditioned media transfer experiments demonstrating that oligodendrocyte-derived factors from PD model cells activate naive microglia (measured by ≥3-fold increase in IL-6/TNF-α secretion) while microglial conditioned media has minimal oligodendrocyte-activating effect; (3) Human post-mortem spatial transcriptomics or immunofluorescence of PD substantia nigra demonstrating that oligodendrocyte inflammatory markers precede microglial activation in disease-stage tissue (n≥20 cases with staging confirmed).